Valuation: Rezolute Inc

Market Cap 453M 405M 378M 343M 646M 43.84B 651M 4.54B 1.77B 22.29B 1.7B 1.66B 71.67B P/E 2027 *
-6.11x
P/E 2028 * -8.36x
Enterprise Value 453M 405M 378M 343M 646M 43.84B 651M 4.54B 1.77B 22.29B 1.7B 1.66B 71.67B EV / Sales 2027 *
216x
EV / Sales 2028 * 8.38x
Free-Float
90.26%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: Rezolute Inc

Manager TitleAgeSince
Chief Executive Officer 58 29/01/2013
Director of Finance/CFO 52 22/01/2024
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 03/05/2022
Director/Board Member 55 19/11/2019
Chairman 68 09/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-14.41% - - 453M
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-0.97%+23.51%+79.57% 58.81B
+0.17%+0.35%+6.85%+34.55% 48.45B
-0.16%-2.21%+331.03%+688.10% 42.84B
-0.50%-3.71%+28.88%+29.73% 42.79B
+0.48%-0.44%+6.65%+110.86% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-2.07%+1.16%+35.00%+26.28% 30.28B
+0.52%-1.85%-9.03%-11.74% 24.05B
Average +0.25%-0.25%+53.49%+122.69% 43.81B
Weighted average by Cap. +0.67%-0.54%+56.36%+129.00%

Financials

2027 *2028 *
Net sales 2.09M 1.87M 1.75M 1.59M 2.99M 203M 3.01M 20.98M 8.2M 103M 7.86M 7.69M 331M 54.09M 48.33M 45.09M 40.96M 77.13M 5.23B 77.71M 542M 212M 2.66B 203M 199M 8.55B
Net income -79.48M -71.02M -66.26M -60.18M -113M -7.69B -114M -796M -311M -3.91B -298M -292M -12.57B -59.93M -53.55M -49.96M -45.38M -85.47M -5.8B -86.11M -600M -235M -2.95B -225M -220M -9.48B
Net Debt - -
Logo Rezolute Inc
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Rezolute Inc